Concentration –QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

ConclusionQTcF increase was dependent on quizartinib and AC886 concentrations, but patient factors, including sex and age, did not affect the concentration –QTcF relationship. Because concomitant strong cytochrome P450 3A (CYP3A) inhibitor use significantly increases quizartinib concentration, these results support the clinical recommendation of quizartinib dose reduction in patients concurrently receiving a strong CYP3A inhibitor.Clinical Trial RegistrationNCT02039726 (registered January 20, 2014).
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research